Psoriasis and cardiovascular comorbidity – a mutually aggravating relationship
https://doi.org/10.21518/ms2023-102
Abstract
Introduction. The systemic psoriatic process affects not only the skin, but also other organ systems, including the cardiovascular system. Immunopathological inflammation that occurs in the skin and articular tissues is a central link in the pathology of the cardiovascular system in psoriasis.
Objective. Identify diseases of the cardiovascular system and factors of their development in patients with psoriasis and to assess their severity depending on the severity of dermatosis.
Materials and methods. The study included 406 patients with psoriasis aged 18 to 74 years, who were divided into three subgroups depending on the severity of the course. Assessment of the state of the cardiovascular system was carried out using the following methods: uestionnaire, clinical, physical, laboratory and statistical. The comparison group consisted of 200 people.
Results. In 53.9% of patients, psoriasis occurred against the background of cardiovascular comorbidity. More than 90% of patients with moderate to severe psoriasis have more than three risk factors for CCC diseases. Patients are more susceptible to the development of hypertension, hypercholesterolemia, obesity, abdominal obesity, stress and smoking. The higher the cardiovascular risk, the more severe psoriasis is.
Conclusions. The presence of unmodified and modifiable risk factors for the development of cardiovascular diseases is aggravating for the course of psoriasis, which means that the risk of undesirable fatal events is higher. Patients with psoriasis need additional preventive measures aimed at preventing the development of cardiovascular pathology.
About the Authors
Yu. S. Kovaleva
Altai State Medical University
Russian Federation
Russian Federation
Julia S. Kovaleva - Dr. Sci. (Med.), Associate Professor, Head of the Department of Dermatovenerology.
40, Lenin Ave., Barnaul, Altai Krai, 656038
A. A. Vedler
Altai State Medical University
Russian Federation
Russian Federation
Anna A. Vedler - Assistant of the Department of Dermatovenerology.
40, Lenin Ave., Barnaul, Altai Krai, 656038
References
1. Askhakov M.S., Chebotaryov V.V. Psoriasis: the modern idea of dermatosis. Medical News of North Caucasus. 2017;12(2):225–229. (In Russ.) https://doi.org/10.14300/mnnc.2017.12065.
2. Barashkova N.P., Petrova L.I. Analysis of the incidence of psoriasis and methods of treatment among children in the Sakha (Yakutia) Republic in 2013–2015. Medicus. 2016;6(12):43–45. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=27237859.
3. Kojanov A.S. Epidemiological and clinical features of psoriasis present stage. Kyrgyzstan Medicine. 2015;(1):34–37. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=27701532.
4. Kubanov A.A. (ed.). Psoriasis. Clinical recommendations. Moscow; 2023. (In Russ.) Available at: https://diseases.medelement.com/disease/псориазкр-рф-2023/17540.
5. Zykova O.S. Features of the dermatological status in arthropathic psoriasis. In: Achievements of fundamental, clinical medicine and pharmacy: materials of the 69th scientific session of the University staff. Vitebsk, January 29–30, 2014. Vitebsk: Vitebsk State Medical University; 2014. (In Russ.) Available at: https://www.elibrary.ru/download/elibrary_23153552_92498757.pdf.
6. Oliveira Mde F., Rocha Bde O., Duarte G.V. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20. https://doi.org/10.1590/abd1806-4841.20153038.
7. Padhi T., Garima. Metabolic syndrome and skin: psoriasis and beyond. Indian J Dermatol. 2013;58(4):299–305. https://doi.org/10.4103/0019-5154.113950.
8. Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007–1011. https://doi.org/10.1111/j.1468-3083.2011.04065.x.
9. Li J., Niu B., Wang X., Hu H., Cao B. A case report of hereditary neuropathy with liability to pressure palsies accompanied by type 2 diabetes mellitus and psoriasis. Medicine (Baltimore). 2017;96(19):e6922. https://doi.org/10.1097/MD.0000000000006922.
10. Puig L. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Int J Mol Sci. 2017;19(1):58. https://doi.org/10.3390/ijms19010058.
11. Rodríguez- Zúñiga M.J.M., García- Perdomo H.A. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017;77(4):657–666.e8. https://doi.org/10.1016/j.jaad.2017.04.1133.
12. Singh S., Young P., Armstrong A.W. An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. PLoS ONE. 2017;12(7):e0181039. https://doi.org/10.1371/journal.pone.0181039.
13. Utz S.R., Juke A.N. Psoriasis, cardiovascular syndrome and methotrexate. Saratov Journal of Medical Scientific Research. 2016;12(3):490–492. (In Russ.) Available at: https://www.elibrary.ru/download/elibrary_28802397_13832528.pdf.
14. Cao L.Y., Soler D.C., Debanne S.M., Grozdev I., Rodriguez M.E., Feig R.L. et al. Psoriasis and cardiovascular risk factors: increased serum myeloperoxidase and corresponding immunocellular overexpression by Cd11b(+) CD68(+) macrophages in skin lesions. Am J Transl Res. 2013;6(1):16–27. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853421.
15. Murashkin N.N., Kubanova A.A. Current clinical features in the course of psoriasis and psoriasiform states in children. Vestnik Dermatologii i Venerologii. 2011;(2):38–43. (In Russ.) Available at: https://elibrary.ru/item.asp?id=16378680.
16. Dontsova E.V., Olisova O.Yu., Rakhmanova V.A., Kruglova L.S. Psoriasis and metabolic syndrome: mechanisms of comorbidity. Medical Alphabet. Dermatology. 2019;7(382):34–38. (In Russ.) Available at: https://www.med-alphabet.com/jour/article/viewFile/1045/880.
17. Takeshita J., Grewal S., Langan S.M., Mehta N.N., Ogdie A., Van Voorhees A.S., Gelfand J.M. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol. 2017;76(3):393–403. https://doi.org/10.1016/j.jaad.2016.07.065.
18. Visseren F.L.J., Mach F., Smulderst Y.M. Carballo D., Koskinas K., Bäck M. et al. Recommendations of the European Society of Cardiologists on the prevention of cardiovascular diseases in clinical practice 2021. Russian Journal of Cardiology. 2022;27(7):191–288. (In Russ.) https://doi.org/10.15829/1560-4071-2022-5155.
19. Swindell W.R., Stuart P.E., Sarkar M.K., Voorhees J.J., Elder J.T., Johnston A., Gudjonsson J.E. Cellular dissection of psoriasis for transcriptome analyses and the post- GWAS era. BMC Med Genomics. 2014;7:27. https://doi.org/10.1186/1755-8794-7-27.
20. Yang H., Brand J.S., Li J., Ludvigsson J.F., Ugalde- Morales E., Chiesa F. et al. Risk and predictors of psoriasis in patients with breast cancer: a Swedish population- based cohort study. BMC Med. 2017;15(1):154. https://doi.org/10.1186/s12916-017-0915-4.
21. Rotanov S.V., Rezaykina A.V., Znamenskaya L.F. Vascular endothelial growth factor in patients with psoriasis. Kliniko- Laboratornyy Konsilium. 2013;(2–3): 50–53. (In Russ.) Available at: https://elibrary.ru/item.asp?id=22701961.
22. Slesarenko N.A., Utz S.R., Shtoda U.M., Platonova A.N. Endothelial dysfunction with psoriasis and type 2 diabetes mellitus in conditions of comorbidity. Saratov Journal of Medical Scientific Research. 2013;9(3):590–595. (In Russ.) Available at: https://elibrary.ru/item.asp?id=21156675.
23. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741. https://doi.org/10.1001/jama.296.14.1735.
24. Kondratieva Yu.S., Vedler A.A. Assessment of risk factors for diseases of the cardiovascular system in patients with psoriasis. Medical Review. Science and Practice. 2016;1(5):34–38. (In Russ.) Available at: https://cyberleninka.ru/article/n/otsenka-faktorov-riska-zabolevaniyserdechno-sosudistoy-sistemy-u-patsientov-s-psoriazom/viewer.
25. Boytsov S.A., Pogosova N.V., Bubnova M.G., Drapkina O.M., Gavrilova N.E., Yeganyan R.A. et al. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;23(6):7–122. (In Russ.) http://doi.org/10.15829/1560-4071-2018-6-7-122.
26. Kim G.K., Del Rosso J. Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol. 2010;3(1):32–38. Available at: https://pubmed.ncbi.nlm.nih.gov/20725536/.
27. Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V. Arterial hypertension in adults: Clinical Guidelines. Moscow; 2022. (In Russ.) Available at: https://scardio.ru/content/Guidelines/project/KR_AG.pdf.
28. Borovikov V.P. STATISTICA: the art of data analysis on a computer for professionals. St Petersburg: Piter; 2003. 688 p. (In Russ.) Available at: https://search.rsl.ru/ru/record/01001860859.
Review
For citations:
Kovaleva YS, Vedler AA. Psoriasis and cardiovascular comorbidity – a mutually aggravating relationship. Meditsinskiy sovet = Medical Council. 2023;(13):24-31. (In Russ.) https://doi.org/10.21518/ms2023-102
Views:
1072
Email this article 